SCHEMBL2198261

SCHEMBL2198261

Cc1n[nH]cc1C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.31
NOTUM Q6P988 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25316524 0.84
SCHEMBL1106086 0.78 KCNH2 (0.33)
SCHEMBL6904864 0.76
SCHEMBL2528825 0.73
SCHEMBL20734528 0.73
SCHEMBL11192096 0.71 L3MBTL1 (0.32) NOTUM
SCHEMBL31532399 0.71 NOTUM (0.30) NOTUM
SCHEMBL28114069 0.71 CACNA1H (0.32) NOTUM
SCHEMBL21646570 0.71
SCHEMBL23515079 0.71 NOTUM (0.32) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109504497-A A kind of high-temperature anticorrosion renovation agent and preparation method thereof 内蒙古三业科技开发有限公司 2019-03-22 CN claimed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 EP disclosed
US-12258327-B2 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2025-03-25 US disclosed
US-20240246960-A1 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2024-07-25 US disclosed
EP-4305031-A1 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR Admare Therapeutics Society (CA) 2024-01-17 EP disclosed
WO-2022213204-A9 CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER REPARE THERAPEUTICS INC. (CA) 2023-11-16 WO disclosed
WO-2023193114-A1 METHODS OF USING ATR INHIBITORS REPARE THERAPEUTICS INC. (CA) 2023-10-12 WO disclosed
US-20230085912-A1 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS YUHAN CORPORATION (KR) 2023-03-23 US disclosed
WO-2023027516-A1 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS YUHAN CORPORATION (KR) 2023-03-02 WO disclosed
WO-2022261777-A1 USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER REPARE THERAPEUTICS INC. (CA) 2022-12-22 WO disclosed
US-20100063063-A1 Substituted Heteroaryls PFIZER INC 2010-03-11 US disclosed
US-7396939-B2 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides BAYER CROPSCIENCE GMBH (DE) 2008-07-08 US disclosed
US-7396939-B2 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides BAYER CROPSCIENCE GMBH (DE) 2008-07-08 US disclosed
EP-1824338-B1 3-CYCLOPROPYL-4-(3-AMINO-2-METHYLBENZOYL)PYRAZOLS AND THE USE OF THE SAME AS HERBICIDES BAYER CROPSCIENCE AG (DE) 2008-03-19 EP disclosed
US-7312180-B2 Substituted 4-(4-trifluoromethylpyrazolyl)pyrimidines BAYER CROPSCIENCE GMBH (DE) 2007-12-25 US disclosed
US-7312180-B2 Substituted 4-(4-trifluoromethylpyrazolyl)pyrimidines BAYER CROPSCIENCE GMBH (DE) 2007-12-25 US disclosed
US-7312180-B2 Substituted 4-(4-trifluoromethylpyrazolyl)pyrimidines BAYER CROPSCIENCE GMBH (DE) 2007-12-25 US disclosed
EP-1725103-A1 SUBSTITUTED 4-(4-TRIFLUOROMETHYLPYRAZOLYL)-PYRIMIDINES SERVING AS HERBICIDES Bayer CropScience GmbH (DE) 2006-11-29 EP disclosed
WO-2005089551-A1 SUBSTITUTED 4-(4-TRIFLUOROMETHYLPYRAZOLYL)-PYRIMIDINES SERVING AS HERBICIDES BAYER CROPSCIENCE GMBH (DE) 2005-09-29 WO disclosed
US-20050209106-A1 Substituted 4-(4-trifluoromethylpyrazolyl)pyrimidines BAYER CROPSCIENCE GMBH (DE) 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230085912-A1 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 HSD11B1 4847/4885NOTUM 3618/4885
US-20240246960-A1 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor DCK, ERCC2, POLK HSD11B1 4006/4885NOTUM 4721/4885
US-20050209106-A1 Substituted 4-(4-trifluoromethylpyrazolyl)pyrimidines CYP4X1, DDT, CYP4F3 HSD11B1 3109/4885NOTUM 2837/4885
US-12258327-B2 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors EGFR, ERBB2, ERBB4 HSD11B1 4847/4885NOTUM 3618/4885
US-20100063063-A1 Substituted Heteroaryls GCKR, GCK, GALK1 HSD11B1 498/4885NOTUM 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.